Apogee Therapeutics, Inc. Common StockAPGE
▲ ポジティブ資本関連度
Acquisition at $135.11 per share, a 49.5% premium, is positive for shareholders.
資産への影響 2
Biotech & Genomic Medicine
Apogee Therapeutics, Inc. Common Stock
AbbVie IncABBV
▲ ポジティブ資本関連度
Acquiring Apogee at a premium expands AbbVie's pipeline, though the article focuses on Baron's exit.
テーマインパクト
カバレッジ外企業 1
Baron Capital非上場± 混在
関連度